| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |



From the Robert H. Lurie Comprehensive Cancer Center* and the Departments of Pediatrics
and Pathology,
Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| Abstract |
|---|
|
|
|---|
NB tumors consist of two main cell populations, neuroblastic/ganglionic cells and Schwann cells, and the quantity of schwannian stroma directly correlates with the tumor maturation.4,5 A paucity of schwannian stroma is seen in undifferentiated tumors, whereas differentiating or differentiated neuroblasts that histologically resemble ganglion cells are seen in tumors with abundant schwannian stroma. The origin of the Schwann cells and their role in regulating the maturation of tumor cells remain controversial. Schwann cells in maturing NB tumors appear to lack the genetic anomalies found in the neuroblastic cells,6 suggesting that they are reactive cells recruited from the surrounding nonneoplastic tissue. On the basis of known interactions between neuroblasts and their supporting stroma, Ambros and colleagues6 speculated that the recruited Schwann cells induced neuroblast differentiation by producing anti-proliferation and prodifferentiation factors. However, other studies indicate that the stromal cells and neuroblasts may originate from a common neoplastic stem cell. In one report, shared genetic abnormalities were identified in cultured stromal-like cells and neuroblasts derived from involved bone marrow.7 Other investigators have reported identical genetic alterations in neuroblastic and nonneuronal cells derived from NB tumors.8
The favorable prognostic impact of schwannian stroma has been emphasized in the International Neuroblastoma Pathology Classification System.5 Most tumors with abundant schwannian stroma are classified as favorable histology and are associated with high rates of cure.5,9 These observations indicate that Schwann cells may be capable of influencing NB phenotype, and several laboratory studies support this hypothesis. Kwiatkowski and colleagues10 have shown that Schwann cell-conditioned medium promotes NB differentiation in vitro. NB differentiation is also induced when NB cells and Schwann cells are co-cultured.11 In addition, we and others have shown that Schwann cells produce potent inhibitors of angiogenesis that play a key role in mediating the anti-tumor activity of Schwann cell-conditioned media.12-14
To directly investigate the in vivo effects of cross-talk between Schwann cells and neuroblasts, we developed a novel NB xenograft model in which human SMS-KCNR NB cells were inoculated into mouse sciatic nerves. For negative controls, NB cells were inoculated outside the sciatic nerve. Our results demonstrate that infiltrating mouse Schwann cells are capable of influencing NB tumor proliferation, differentiation, apoptosis, and angiogenesis in vivo.
| Materials and Methods |
|---|
|
|
|---|
Female athymic nude mice (Harlan, Indianapolis, IN), 6 to 7 weeks old, were anesthetized by an intraperitoneal injection of 30 µl of a ketamine and xylazine mixture at a ratio of 5:3. The left sciatic nerve was surgically exposed. Cultured human SMS-KCNR NB cells were washed three times in media, and resuspended in RPMI 1640 complete media at a concentration of 5 x 105 cells per 5 µl. SMS-KCNR NB cells (5 x 105) were microinjected into the left sciatic nerve of 19 mice using a 10-µl Hamilton syringe as previously described.15 In control animals, the same number of NB cells were microinjected outside the sciatic nerve (n = 12). Tumor volume, [(length x width)2/2], was measured once a week. Animals were sacrificed when tumors were >500 mm3, and the tumors were harvested for histological and immunohistochemical evaluation. All animals were treated according to the National Institutes of Health guidelines for animal care and use, following protocols approved by the Animal Care and Use Committee at Northwestern University.
Tissue Processing
Xenograft tissue sections (3 mm thick) were cut at maximum diameter, fixed in 10% formaldehyde/zinc fixative (Electron Microscopy Sciences, Hatfield, PA), and embedded in paraffin. The adjacent portion of tissue was frozen with liquid nitrogen and embedded in O.C.T. compound (Sakura Finetech, Torrance, CA). Four-µm-thick serial paraffin sections were heated at 57°C for 60 minutes, deparaffinized in CitriSolv (Fisher, Pittsburgh, PA) two times for 5 minutes, and rehydrated in graded ethanol and deionized water. Sections of each tumor were stained with hematoxylin and eosin for histological evaluation. Frozen sections were fixed with cold acetone for 15 minutes and stored at 80°C until staining. Adjacent sections were used for immunohistochemistry and in situ hybridization.
Immunohistochemistry
Antigen retrieval was performed with 10 mmol/L citrate buffer (pH 6.0) for S-100, GAP-43, p75NGFR, Ki-67, human leukocyte antigen (HLA) class I, and major histocompatibility complex (MHC) class Ib antibodies, and with 1 mmol/L ethylenediaminetetraacetic acid (pH 8.0) for CD31 antibody, heated in a boiling steamer for 20 minutes, and then cooled down to room temperature for 20 minutes. Sections were incubated with the following primary antibodies: mouse monoclonal S-100 (Ab-1, clone 4C4.9, 1:100; NeoMarkers, Fremont, CA) that is reactive with both human and mouse; mouse anti-GAP-43 (clone 7B10, 1:200; Zymed Lab. Inc., San Francisco, CA) that is reactive with human and mouse; mouse anti-human p75NGFR (ab10495, clone ME20.4, 1:200; Abcam, Cambridge, MA); polyclonal rabbit anti-mouse p75NGFR (1:800, Abcam); monoclonal mouse anti-human Ki-67 (clone MIB-1, 1:200; DakoCytomation, Carpinteria, CA); monoclonal rat anti-human HLA class I (clone YTH 862.2, 1:1000; Serotec, Raleigh, NC); monoclonal hamster anti-mouse MHC class Ib (130) (1:200; Santa Cruz Biotechnology Inc., Santa Cruz, CA); and polyclonal goat anti-mouse CD31 (PECAM-1, M-20, 1:100; Santa Cruz Biotechnology Inc.). The sections were incubated in a humidity chamber overnight at 4°C, bridged with peroxidase labeled-dextran polymer to avoid nonspecific staining, and visualized with diaminobenzidine (DAKO EnVision Plus System, DakoCytomation). The HLA, MHC, and CD31 primary antibodies were linked by biotinylated rabbit anti-rat, goat anti-hamster, or horse anti-goat IgG, respectively, at a concentration of 1:200 for each secondary antibody and streptavidin (1:400; Vector Laboratories, Burlingame, CA). Sections were counterstained with Gills hematoxylin. The following tissues and cell lines served as positive or negative controls, respectively, for antigen expression: S-100 (human schwannoma and mouse sciatic nerve versus the human NBL-W-N NB cell line), GAP-43 (human brain and pancreas versus NBL-W-N), MHC class Ib (human Schwannoma versus mouse kidney), HLA class I (mouse tail versus human kidney), human p75NGFR (human schwannoma versus NBL-W-N), mouse p75NGFR (mouse sciatic nerve versus NBL-W-N), and CD31 (mouse kidney served as both positive and negative controls). The control tissues and cell lines were processed in the same manner as the xenografts. In additional control experiments, the primary antibodies were omitted. All immunostainings were performed on paraffin-embedded sections except the rat anti-human HLA class I antibody, which was performed on frozen sections. To ensure specificity and sensitivity, the amount of antibody used in the studies was carefully optimized to the level with maximal positivity without microscopically visible background on the control tissues described above. To ensure the consistency of the immunoassays, all 31 samples plus negative and positive controls were stained at one time for each marker using the same conditions. Brown staining in the cytoplasm, membrane, or nucleus of the neuroblasts, Schwann cells, or endothelial cells was scored as positive.
Immunofluorescence
Histological sections of the NB xenografts were double-stained with anti-S-100 and specific anti-mouse or anti-human p75NGFR antibodies. Antigens were retrieved using 10 mmol/L citrate buffer at pH 6.0 and blocked with 10% normal horse serum and CAS universal blocking reagent (Zymed) for 15 minutes each at room temperature to minimize species cross reactivity. The concentrations were 1:100 for S-100, and 1:100 and 1:400 for the p75NGFR anti-mouse and anti-human primary antibodies, respectively. A concentration of 1:200 was used for both the anti-mouse Texas Red and anti-rabbit fluorescein isothiocyanate-labeled secondary antibodies. The nuclei were counterstained with 4,6-diamidino-2-phenylindole (Vector Laboratories).
Quantification of S-100-Positive Schwann Cells
S-100-positive Schwann cells were quantified by counting 10 consecutive high-power (x400 magnification) fields starting at the area with the highest density of S-100-positive cells. The total of the mean S-100-positive Schwann cells was converted to S-100-positive cells per square millimeter.
Semiquantitation of p75NGFR and GAP-43
Cytoplasmic staining was considered as positive for GAP-43 and p75NGFR. Sections with no or
5% NB cells stained with GAP-43 were scored as 0. Whole tumor sections with >5% and
25% NB cells stained with GAP-43 were scored as 1+; >25% and
50% were scored as 2+; >50% were scored as 3+. For p75NGFR, tumor sections with
5% positive neuroblasts or Schwann cells were scored as negative. Sections with >5% p75NGFR-stained neuroblasts or Schwann cells were scored as positive.
Quantification of Apoptosis and MIB-1 (Ki-67) Labeling
In situ detection of cleaved, apoptotic DNA fragments was performed on 31 xenografts using the In Situ Cell Death Detection kit (Roche Diagnostics Corp., Indianapolis, IN) as described previously.16 Briefly, rehydrated paraffin sections of xenografts were digested with 20 µg/ml Proteinase K in 10 mmol/L Tris hydrochloride buffer (pH 7.6) at room temperature for 20 minutes and blocked with CAS (Zymed) and TSA (Perkin-Elmer Life Sciences, Boston, MA) blocking solutions at room temperature for 15 and 30 minutes, respectively. Sections were incubated with a mixture of terminal dUTP nick-end labeling (TUNEL) enzyme solution and label solution at a ratio of 1:10 in a humidity chamber at 37°C for 60 minutes. The reaction was terminated with 1% Tween 20 in 1x Tris-buffered saline buffer at room temperature for 10 minutes, and counterstained and shielded with VectaShield containing 4,6-diamidino-2-phenylindole (Vector Laboratories, Inc.). Sections of human colon mucosa processed similarly to the xenografts were included in each assay. To check for intra- and interassay consistency, the apoptotic bodies in colonic mucosa, stained as the first and the last slide of each assay, were assessed. The assays were considered adequate only when the frequencies of apoptosis on the two sections of colonic mucosa were similar. Each TUNEL in situ-labeled section was quantified at a magnification of x400 using a Leica DM IRB inverted fluorescence microscope equipped with Image-Pro Plus Version 4.5 software (Media Cybernetics, Silver Spring, MD). The frequency of labeled apoptotic cells was obtained by quantifying 10 consecutive fields starting with areas with the highest number of TUNEL-labeled nuclei, avoiding areas of necrosis, and expressed as apoptosis per 10 high-power fields (HPFs). The MIB-1 (Ki-67)-labeled proliferating cells were quantified and expressed in the same way as TUNEL-labeled apoptosis.
Quantification of Angiogenesis
Endothelial cells were highlighted by immunostaining of CD31 on paraffin-embedded xenograft tissue sections. Mean vascular density (MVD) was quantified by counting 10 consecutive HPFs at x400 magnification. The average MVD counted in the 10 fields was converted and expressed as MVD/mm2.
Statistical Analysis
The two-tailed Students t-test was used to compare the statistical significance of differences between the mean values of quantification of S-100, Ki-67, CD31, and apoptosis in the NB xenografts engrafted inside versus outside the sciatic nerve. Fishers exact test was used to test the significance of difference of frequency of p75NGFR and GAP-43 expression in the xenografts that developed within the sciatic nerve versus controls.
| Results |
|---|
|
|
|---|
Tumor volumes were measured in 11 mice after intrafascicular tumor inoculation and in 6 controls. Surprisingly, the sciatic nerve-engrafted xenografts initially grew more rapidly than controls. Three weeks after microinjection of the NB tumor cells into the sciatic nerve, palpable tumors were detected in 3 of 11 mice. By 4 weeks, tumors were detected in 6 of the 11 animals. In contrast, none of the control tumors were palpable at 3 weeks, and only two of six mice had tumors by 4 weeks. At 5 weeks the average size of tumors engrafted within the nerve was 30 mm3 compared to 3 mm3 for control animals (P = 0.021). Although the sciatic nerve-engrafted tumors were also larger than controls at 6 and 7 weeks, the difference in size was no longer statistically significant (P = 0.066 and P = 0.23, respectively).
Mouse Schwann Cells Infiltrate Human NB Xenografts
To confirm the location of the NB xenografts in relation to the mouse sciatic nerve, histological sections of the xenografts were examined. Schwann cells in the mouse sciatic nerve were identified by routine morphology and by immunohistochemical staining with S-100 antibody (Figure 1; A to D)
. In 12 of the 19 NB xenografts that developed after tumor cell inoculation into the sciatic nerve, the tumor was completely encased by the nerve, and in the remaining animals the sciatic nerve was in direct contact with tumor cells. All 12 control tumors grew in close proximity to the sciatic nerve, although none of the tumors were encased by the nerve tissue. Infiltrating Schwann cells were detected by immunohistochemistry in all 19 NB xenografts engrafted in the sciatic nerve, with an average of 240 ± 136 Schwann cells/mm2 (Figure 1E)
. In contrast, Schwann cells were not identified in 9 of the 12 control tumors, and the remaining 3 tumors contained significantly fewer numbers of Schwann cells (14 ± 13 cells/mm2, P < 0.001) (Figure 1F)
.
|
|
|
The morphological features of the NB cells in the xenografts that developed inside versus outside the sciatic nerve differed. Large differentiating neuroblasts with abundant eosinophilic cytoplasm were present in the NB xenografts engrafted within the nerve (Figure 1G)
. In contrast, undifferentiated NB cells with high nuclear:cytoplasmic ratios were seen in the control tumors (Figure 1H)
. Numerous mitotic and karyorrhectic cells were also detected in the control tumors, which are histological features of high cell turnover and one of the criteria for unfavorable histology NB.5
To further evaluate the maturation of the NB cells, tumor sections were immunostained with GAP-43, a protein synthesized at high levels during axonal outgrowth and a marker of neuronal differentiation.17,18
In the xenografts engrafted within the sciatic nerve, >50% of the tumor cells were positive for GAP-43 expression (17 of 19 scored as 2+ or 3+), whereas 0 to
25% of the NB cells in control xenografts weakly reacted with GAP-43 (11 of 12 scored as 0 or 1+, P < 0.001) (Table 1
; Figure 1, I and J
).
|
Tumor cell proliferation was examined by evaluating Ki-67 expression,19
a nuclear protein that is preferentially expressed during active phases of the cell cycle. Significantly higher rates of neuroblast proliferation were detected in the control tumors compared to the tumors that developed within the sciatic nerve (525 ± 159 per 10 HPFs versus 295 ± 139 per 10 HPFs, respectively; P = 0.00049) (Figure 4; A to E)
. TUNEL assays were performed on the NB xenografts to determine whether the frequency of apoptotic cells differed in the tumors engrafted inside versus outside the sciatic nerve. As shown in Figure 4, F to J
, a significantly higher number of apoptotic cells were seen in the xenografts engrafted inside the sciatic nerve compared to controls (73 ± 45 per 10 HPFs versus 36 ± 13 per 10 HPFs, respectively; P = 0.0023).
|
We also examined the MVDs of the NB xenografts to determine whether tumor vascularity was influenced by the infiltrating Schwann cells. A significantly lower MVD was observed in the xenografts engrafted inside the sciatic nerve compared to controls (50 ± 13.05/mm2 versus 113 ± 32.85/mm2, respectively; P = 0.00025) (Figure 5)
.
|
| Discussion |
|---|
|
|
|---|
In addition to increased numbers of infiltrating Schwann cells, the sciatic nerve-engrafted xenografts contained NB cells with a more differentiated phenotype, higher numbers of apoptotic cells, lower numbers of proliferating neuroblasts, and lower numbers of blood vessels than control tumors. Because these are characteristics that are seen in NB tumors with favorable prognosis,5,21 we were surprised that the sciatic nerve-engrafted xenografts initially grew at a more rapid rate than controls. It is possible that the sciatic nerve may provide an environment that promotes tumorigenic growth. Recent studies have shown that human neurofibromatosis type 1 (NF1) Schwann cells do not form tumors when inoculated in mice subcutaneously, but they were capable of forming tumors in the sciatic nerve.22 The neuroblasts in the sciatic nerve-engrafted tumors were larger with more abundant cytoplasm than those in the control tumors. Thus, the initial increase in tumor volume in the tumors that developed within the sciatic nerve may also be consequent to the larger size of the more differentiated tumor cells.
Schwann cells secrete several potent angiogenesis inhibitors,12-14 and it is likely that these factors were responsible for the lower MVD observed in the sciatic nerve-engrafted xenografts compared to controls. Schwann cells also produce a number of neurotrophic factors including nerve growth factor, brain-derived neurotrophic factor, and ciliary neurotrophic factor23,24 that are known to induce the differentiation of neuronal cells. Others have shown that factors secreted by Schwann cells are capable of inducing NB differentiation in vitro.10,11 Thus, it is likely that the neuroblast differentiation observed in the sciatic nerve-engrafted tumors was similarly induced by these neurotrophins. Neurotrophins also regulate neuronal cell survival and death.25,26 Others have reported a marked increase in the rate of NB apoptosis after 10 days of co-culture with Schwann cells,11 and we, similarly, found an enhanced rate of NB apoptosis in the xenografts that contained infiltrating Schwann cells.
In the study reported by Ambros and co-workers,6 only NB tumors with favorable genetic features showed spontaneous development of Schwann cell stroma, suggesting that triploidy and the absence of 1p deletions in NB cells may be prerequisites for spontaneous maturation. The SMS-KCNR NB cells used in our tumor model have several unfavorable genetic features including MYCN amplification, chromosome 1p deletion, and chromosome 17q gain.27 Nevertheless, in the presence of the infiltrating Schwann cells, the phenotype of the SMS-KCNR xenografts was modified. Thus, although favorable genetic features may be a prerequisite for the NB cells to produce factors that attract Schwann cells to invade tumors, once the Schwann cells are present, they appear to be capable of influencing the biology of genetically favorable as well as unfavorable NB cells. Unfortunately, we were not able to determine the fate of the sciatic nerve-engrafted tumors in long-term studies because animals had to be sacrificed as soon as the tumors caused morbidity.
In 1889, Dr. Stephen Paget28 first suggested that interactions between tumor cells and cells in tissue microenvironments are critical in regulating tumorigenesis when he published his seminal "seed and soil" hypothesis to explain the nonrandom pattern of metastasis. More recent studies have emphasized the importance of a number of components of the "soil" in regulating tumor growth including: 1) the extracellular matrix and matricellular proteins, 2) stromal cells and their growth factors and inhibitors, 3) microvessels and angiogenesis factors, 4) immune cells and their cytokines; and 5) inflammatory cells.29 There is now substantial evidence that tumor growth and progression is dependent on cross-talk between malignant cells and their adjacent stromal compartment.30 Our results demonstrate that infiltrating Schwann cells are capable of promoting neuroblast differentiation, inducing apoptosis, and inhibiting angiogenesis and proliferation in NB xenografts. Further research investigating the molecules involved in the cross-talk between Schwann cells and neuroblasts may lead to a new paradigm for treating NB. Perhaps in addition to developing new therapies that target the "seed", strategies should also be focused on enhancing the components of the "soil" that inhibit tumor growth.
| Footnotes |
|---|
Supported in part by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (grant NS049814), the Neuroblastoma Childrens Cancer Society, Friends for Steven Pediatric Cancer Research Fund, the Elise Anderson Neuroblastoma Research Fund, the North Suburban Medical Research Junior Board, and the Robert H. Lurie Comprehensive Cancer Center (National Institutes of Health, National Cancer Institute core grant 5P30CA60553).
Accepted for publication November 18, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Peddinti, R. Zeine, D. Luca, R. Seshadri, A. Chlenski, K. Cole, B. Pawel, H. R. Salwen, J. M. Maris, and S. L. Cohn Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma Clin. Cancer Res., June 15, 2007; 13(12): 3499 - 3506. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yang, Y. Tian, S. Liu, R. Zeine, A. Chlenski, H. R. Salwen, J. Henkin, and S. L. Cohn Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma Cancer Res., February 15, 2007; 67(4): 1716 - 1724. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Naef and J. Huelsken Cell-type-specific transcriptomics in chimeric models using transcriptome-based masks Nucleic Acids Res., July 19, 2005; 33(13): e111 - e111. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |